ELAN Trial DOAC Dosing for Stroke Prevention in Atrial Fibrillation
Standard Stroke-Prevention Doses
The ELAN trial used the FDA-approved stroke-prevention doses for each DOAC, which are:
Apixaban
- Standard dose: 5 mg twice daily 1
- Reduced dose: 2.5 mg twice daily when ≥2 of the following criteria are met: 1, 2
- Age ≥80 years
- Body weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL (or CrCl 15–29 mL/min)
Rivaroxaban
Dabigatran
- Standard dose: 150 mg twice daily 1
- Alternative dose: 110 mg twice daily (no pre-specified dose-reduction criteria in the pivotal trial, though this lower dose was studied) 1
- Dose adjustments per SmPC: 110 mg twice daily if age ≥80 years, concomitant verapamil, or increased risk of GI bleeding 1
Edoxaban
- Standard dose: 60 mg once daily 1
- Reduced dose: 30 mg once daily when any of the following are present: 1
- Body weight ≤60 kg
- CrCl ≤50 mL/min
- Concomitant therapy with strong P-glycoprotein inhibitor
Critical Dosing Distinctions Between Agents
Apixaban requires the strictest criteria for dose reduction—meeting ≥2 of 3 factors—whereas edoxaban and rivaroxaban reduce dose based on a single criterion (renal function or weight). 1, 2 This makes apixaban less likely to be inappropriately underdosed in clinical practice, though studies show 9.4–40.4% of apixaban prescriptions involve incorrect underdosing. 3
Dabigatran has the highest renal clearance (≈80%) compared to rivaroxaban (≈66%) and apixaban (≈27%), making it the least suitable option for patients with declining renal function. 1, 2 For CrCl <30 mL/min, dabigatran is contraindicated in Europe and should be avoided in the United States. 1, 4
Renal Function Monitoring Requirements
Calculate creatinine clearance using the Cockcroft-Gault equation (not eGFR), as this method was used in all pivotal trials and FDA labeling. 2, 5 Renal function must be reassessed at least annually, or every 3–6 months when CrCl <60 mL/min. 2, 5
Drug Interaction Adjustments
For apixaban, reduce to 2.5 mg twice daily when using combined P-glycoprotein AND strong CYP3A4 inhibitors (ketoconazole, ritonavir, itraconazole) in patients otherwise receiving 5 mg twice daily. 2, 5 Avoid apixaban entirely with strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin). 2, 5
For edoxaban, the 30 mg dose is required when using concomitant strong P-glycoprotein inhibitors. 1
Common Prescribing Errors to Avoid
Do not reduce apixaban dose based on a single criterion (e.g., age ≥80 years alone or CrCl 30–50 mL/min alone)—this is the most frequent dosing error. 2, 3 Among clinicians treating atrial fibrillation, 41.2% incorrectly underdosed apixaban in scenarios where full dose was indicated. 3
Do not use rivaroxaban or dabigatran in patients with CrCl <15 mL/min or on dialysis; apixaban is the only DOAC with FDA approval in this population (5 mg twice daily, reduced to 2.5 mg twice daily if age ≥80 years OR weight ≤60 kg—only one criterion required for dialysis patients). 2, 4